The import forecast of insulin in dosage forms to Germany shows a slight year-on-year increase: from $682.2 million in 2024 to $692.21 million by 2028. As of 2023, the imports stood slightly lower than the projected $682.2 million for 2024. The variations indicate a steady annual growth rate, supported by a relatively stable compound annual growth rate (CAGR) over the forecast period.

Future trends to watch for include:

Technological advancements in insulin delivery and formulation impacting demand.
Regulatory changes within the European Union affecting pharmaceutical imports.
Shifts in the prevalence of diabetes in Germany that may alter import needs.